Video Directly Observed Therapy (DOT) for Hepatitis C treatment
More deaths are caused by Hepatitis C each year than all other infectious diseases combined. Many providers are hesitant to prescribe HCV treatment with concerns over ongoing substance abuse, risk of reinfection, and low adherence among patients.
For a standard 12-week treatment, some hepatitis C drugs cost upwards of $70,000.
Video DOT is a cost-effective solution to ensure adherence to these life-saving treatments.
Understanding dose-by-dose adherence is essential to help patients successfully complete treatment. Video DOT is an effective tool for patients that require additional support structures.
Directly observed therapy is a proven strategy for helping patients stay adherent to medication. Video DOT empowers relationships between patients and providers that encourage patients to successfully complete treatment.
One in four patients with HCV are denied coverage upon initial request. With documented and verifiable adherence data, more patients can easily obtain prior authorization for treatment.
Frequently Asked Questions
Who uses video DOT for hepatitis C? Private clinics and academic medical centers use video DOT to monitor and manage patients.
My patients live chaotic lives, will video DOT work? Yes, video DOT is an effective adherence strategy for complex populations, but it isn’t a one-size-fits-all solution. While some patients require frequent in-person support, video DOT can serve as a complement to treatment.
- (Learn more) HIPAA-compliant
- Patient app available in 20+ languages
- Custom notifications for patients and providers
- Patients can report side effects at every dose
- View patient- and population-level analytics
- Full training and 24/7 support for patients and providers